EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome

David H McDermott, Daniel Velez, Elena Cho, Edward W Cowen, John J DiGiovanna, Diana V Pastrana, Christopher B Buck, Katherine R Calvo, Pamela J Gardner, Sergio D Rosenzweig, Pamela Stratton, Melissa A Merideth und 8 weitere

Journal of Clinical Investigation · 2023

DOI: 10.1172/jci164918 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von David H McDermott und 19 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases. Hauptthemen laut MEDLINE: Immunologic Deficiency Syndromes, Heterocyclic Compounds, Primary Immunodeficiency Diseases, Warts. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Intramural NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunologic Deficiency SyndromesHeterocyclic CompoundsPrimary Immunodeficiency DiseasesWartsHumansGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationCross-Over StudiesQuality of LifeReceptors, CXCR4

Stichwörter der Autor:innen

Clinical TrialsGenetic diseasesImmunologyInnate immunityNeutrophils

Substanzen

Granulocyte Colony-Stimulating FactorHeterocyclic CompoundsReceptors, CXCR4

Autor:innen und Institutionen

  • Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases.
  • Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
  • Laboratory of Cancer Biology and Genetics and.
  • Laboratory of Cellular Oncology, National Cancer Institute.
  • Department of Laboratory Medicine, Clinical Center.
  • Office of the Clinical Director, National Institute of Dental and Craniofacial Research.

Förderung

  • NCI NIH HHS
  • Intramural NIH HHS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Zitieren

APA

McDermott, D. H., Velez, D., Cho, E., Cowen, E. W., DiGiovanna, J. J., Pastrana, D. V., Buck, C. B., Calvo, K. R., Gardner, P. J., Rosenzweig, S. D., Stratton, P., Merideth, M. A., Kim, H. J., Brewer, C., Katz, J. D., Kuhns, D. B., Malech, H. L., Follmann, D., Fay, M. P., & Murphy, P. M. (2023). A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome. Journal of Clinical Investigation. https://doi.org/10.1172/jci164918

Vancouver

McDermott DH, Velez D, Cho E, Cowen EW, DiGiovanna JJ, Pastrana DV, et al. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome. Journal of Clinical Investigation. 2023. doi:10.1172/jci164918

BibTeX
@article{McDermott2023,
  author = {McDermott, David H and Velez, Daniel and Cho, Elena and Cowen, Edward W and DiGiovanna, John J and Pastrana, Diana V and Buck, Christopher B and Calvo, Katherine R and Gardner, Pamela J and Rosenzweig, Sergio D and Stratton, Pamela and Merideth, Melissa A and Kim, H Jeffrey and Brewer, Carmen and Katz, James D and Kuhns, Douglas B and Malech, Harry L and Follmann, Dean and Fay, Michael P and Murphy, Philip M},
  title = {A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  doi = {10.1172/jci164918}
}
Kostenlos starten →